You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
博瑞醫藥(688166.SH):2024年淨利潤1.96億元 同比減少3.05%
格隆匯 02-27 15:38

格隆匯2月27日丨博瑞醫藥(688166.SH)公佈2024年度業績快報2024年,公司實現營業總收入128,255.16萬元,同比增長8.74%,主要得益於產品銷售收入的增長;歸屬於母公司所有者的淨利潤19,628.50萬元,同比減少3.05%,主要系公司堅持“研發驅動”戰略,BGM0504注射液等產品的研發投入不斷加大帶來期間費用增加等因素所致;歸屬於母公司所有者的扣除非經常性損益的淨利潤18,620.97萬元,同比減少0.06%。2024年末,公司總資產516,636.75萬元,較期初增長2.67%;歸屬於母公司的所有者權益240,136.31萬元,較期初增長1.38%。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account